Information  X 
Enter a valid email address

Physiomics PLC (PYC)

  Print      Mail a friend

Thursday 09 August, 2018

Physiomics PLC

Contract award

RNS Number : 3060X
Physiomics PLC
09 August 2018
 

Physiomics plc

("Physiomics") or ("the Company")

 

 

Contract award

 

Physiomics signs agreement with new European biotech client

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k and it is expected to complete in this calendar year.

 

This initial project will focus on the pre-clinical characterisation of an exciting new anti-cancer agent.  The client has expressed the desire for a partner to support them in the period leading up to and during their agent's early clinical studies.

 

Dr Jim Millen, CEO said: "We are very excited to have signed our fourth new client of 2018 and look forward to working with them over the balance of this year."

 

 

Enquiries:

 

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
CNTEASPNESEPEEF

a d v e r t i s e m e n t